July 27, 2023 03:43 PM EDTUpdated July 28, 04:20 PM
Pharma

Mer­ck touts pos­i­tive PhI­II re­sults for 21-va­lent pneu­mo­coc­cal vac­cine can­di­date

Paul Schloesser

Associate Editor

Mer­ck tout­ed pos­i­tive topline re­sults on Thurs­day sug­gest­ing its ex­per­i­men­tal 21-va­lent pneu­mo­coc­cal con­ju­gate vac­cine can­di­date best­ed Pfiz­er’s 20-va­lent shot in a Phase III tri­al. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times